Advertisement

Chemotherapy Induced Peripheral Neuropathies (CIPNs): A Biobehavioral Approach

  • Rhonda J. Moore
Chapter

Abstract

Pain is a prevalent symptom in patients with cancer. Chemotherapy Induced Peripheral Neuropathies (CIPNs), as a type of cancer related pain, are an increasingly common neuropathic pain syndrome. In this paper, we offer a biobehavioral approach to understanding the development and perhaps the maintenance of CIPNs. First, CIPNs are defined. This is followed by a description of the epidemiology, symptoms, and barriers associated with CIPNs. Following important research from the fields of pain, behavior and psychoneuroimmunology (PNI), we suggest that injury to peripheral nerves after chemotherapeutic treatments initiates immune to brain communication, which further modulates the biological mechanisms through which life experiences and behavior reinforce and likely perpetuate the experience of CIPN.

Keywords

Neuropathic Pain Dorsal Horn Peripheral Nerve Injury Vinca Alkaloid Chemotherapeutic Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hewitt,M, Greenfield,S, Stovall, E. (Eds). Cancer Patient to Cancer Survivor: Lost in Transition. IOM Report, National Academies Press, 2005.Google Scholar
  2. 2.
    Mao JJ, Armstrong K, Bowman MA, Xie SX, Kadakia R, Farrar JT. Symptom burden among cancer survivors: impact of age and comorbidity. Journal of the American Board of Family Medicine. 2007;20(5):434–43.PubMedCrossRefGoogle Scholar
  3. 3.
    von Eschenbach AC. Progress with a purpose: eliminating suffering and death due to cancer. Oncology (Williston Park). 2006;20(13):1691–6.Google Scholar
  4. 4.
    Mako C, Galek K, Poppito SR. J Spiritual pain among patients with advanced cancer in palliative care. Palliative Medicine 2006 Oct;9(5):1106–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Shaiova L. Difficult pain syndromes: bone pain, visceral pain, and neuropathic pain. Cancer Journal 2006;12(5):330–40.CrossRefGoogle Scholar
  6. 6.
    Mystakidou K, Tsilika E, Parpa E, Katsouda E, Galanos A, Vlahos L. Psychological distress of patients with advanced cancer: influence and contribution of pain severity and pain interference. Cancer Nursing 2006;29(5):400–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Trask PC, Teno JM, Nash J. Transitions of care and changes in distressing pain. Journal of Pain and Symptom Management 2006;32(2):104–9).PubMedCrossRefGoogle Scholar
  8. 8.
    Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nature Reviews Neuroscience 2006;7(10):797–809.PubMedCrossRefGoogle Scholar
  9. 9.
    Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing 2007;11(3):361–76PubMedCrossRefGoogle Scholar
  10. 10.
    Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Current Pain and Headache Reports 2006 Aug;10(4):279–87.PubMedCrossRefGoogle Scholar
  11. 11.
    Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Expert Opin Drug Saf. 2004;3(6):535–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement. Journal of Supportive Oncology 2006 Sep;4(8):398–9.PubMedGoogle Scholar
  13. 13.
    Paice JA. Chemotherapy-Induced Peripheral Neuropathy: A Dangerous but Understudied Syndrome. Pain Management SIG Newsletter 2008;17(1). http://onsopcontent.ons.org/Publications/SigNewsletters/pm/pm17.1.html Date accessed: 01/01/2008
  14. 14.
    Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Current Opinion in Neurology. 2007 Dec;20(6):719–25.PubMedGoogle Scholar
  15. 15.
    Paice, JA. Peripheral neuropathy: Experimental findings, clinical approaches. Supportive Oncology 2007;5(2), 61–63.Google Scholar
  16. 16.
    Hausheer, F.H., Schilsky, R.L., Bain, S., Berghorn, E.J., Lieberman, F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology 2006;33, 15–49.PubMedCrossRefGoogle Scholar
  17. 17.
    Dougherty, P. M., Cata, J. P., Cordella, J. V., Burton, A. Weng, H. R. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004;109, 132–142.PubMedCrossRefGoogle Scholar
  18. 18.
    Postma, T. J. , Vermorken, J. B. , Liefting, A. J. , Pinedo, H. M. Heimans, J. J. Paclitaxel-induced neuropathy. Annals of Oncology 1995;6, 489–494.PubMedGoogle Scholar
  19. 19.
    Benoliel R, Epstein J, Eliav E, Jurevic R, Elad S. Orofacial pain in cancer: part I – mechanisms. Journal of Dental Research 2007;86(6):491–505.PubMedCrossRefGoogle Scholar
  20. 20.
    Verstappen, C. C. , Postma, T. J. , Hoekman, K. Heimans, J. J. Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer. Journal of Neurooncology 2003;63, 201–205.CrossRefGoogle Scholar
  21. 21.
    Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Franchi D. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Annals of Oncology 2004;15(9):1439–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Moore, RJ. Transportation Issues in Patients with Cancer. (in preparation, 2008).Google Scholar
  23. 23.
    Moore RJ, Spiegel D. Cancer Culture and Communication. Springer, NY, 2004.Google Scholar
  24. 24.
    England JD, Asbury AK. Peripheral neuropathy. Lancet 2004;363(9427):2151–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology 2000 May;11(5):509–13]PubMedCrossRefGoogle Scholar
  26. 26.
    Postma TJ, Hoekman K, van Riel JM, Heimans JJ, Vermorken JB. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. Journals of Neurooncology 1999;45(3):241–6.CrossRefGoogle Scholar
  27. 27.
    Postma TJ, Heimans JJ, Luykx SA, van Groeningen CJ, Beenen LF, Hoekstra OS, Taphoorn MJ, Zonnenberg BA, Klein M, Vermorken JB. A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma. Annals of Oncology 2000 Apr;11(4):409–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Asbury AK. Peripheral neuropathy. Lancet. 2004;363(9427):2151–61.PubMedCrossRefGoogle Scholar
  29. 29.
    Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nature Neuroscience 2007;10(11):1361–1368.PubMedCrossRefGoogle Scholar
  30. 30.
    Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. European Journal of Cancer 2002 Sep;38(14):1832–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Bogduk, M, eds. Classification of Chronic Pain, 2nd Edition, International Association for the Study of Pain Task Force on Taxonomy. Seattle, Wash: IASP Press; 1994:209–214.Google Scholar
  32. 32.
    Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychological Bulletin 2007;133(4):581–624.PubMedCrossRefGoogle Scholar
  33. 33.
    Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Iconomou A, Kalofonos HP,Chroni E. Peripheral neuropathy induced by administration of cisplatin- andpaclitaxel-based chemotherapy. Could it be predicted? Support Care in Cancer 2005 Aug;13(8):647–51.CrossRefGoogle Scholar
  34. 34.
    Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A meta-analysis Diabetic Medicine 2004;21:114–121.PubMedCrossRefGoogle Scholar
  35. 35.
    Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. Oncology Nursing Forum 2004;31:615–623.PubMedCrossRefGoogle Scholar
  36. 36.
    Almadrones LA. Neurologic complications. In J.M. Yasko (Ed.), Nursing management of symptom associated with chemotherapy. Meniscus Health Care Communications, West Conshohocken, PA. 2001, 5th ed., pp. 215–230.Google Scholar
  37. 37.
    Almadrones LA, Arcot, R. Patient guide to peripheral neuropathy. Oncology Nursing Forum 1999;26:1359–1361.PubMedGoogle Scholar
  38. 38.
    Aloe L, Manni L, Porperzi F, De Santis S, Fiore M. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: Behavioral, structural, and biochemical analysis. Autonomic Neuroscience-Basic and Clinical 2000;86:84–93.CrossRefGoogle Scholar
  39. 39.
    Argoff CE, Katz N, Backonja, M. Treatment of postherpetic neuralgia: A review of therapeutic options. Journal of Pain and Symptom Management 2004;28:396–411.PubMedCrossRefGoogle Scholar
  40. 40.
    Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy. A randomized controlled trial. Neurology 2005;64:26–31.PubMedGoogle Scholar
  41. 41.
    Argyriou AA, Polychronopoulos P, Koustra A, Iconomou G, Gourzis P, Assimakopoulos K, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Supportive Care in Cancer 2006;14:223–229PubMedCrossRefGoogle Scholar
  42. 42.
    Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum 2005;32:305–311.PubMedCrossRefGoogle Scholar
  43. 43.
    Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Experimental Neurology 2003;182:12–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Backonja MM, Serra J. Pharmacologic management part 1: Better-studied neuropathic pain diseases. Pain Medicine 2004;5(Suppl. 1), S28–S47.PubMedCrossRefGoogle Scholar
  45. 45.
    Beydoun A, Backonja MM. Mechanistic stratification of antineuralgic agents. Journal of Pain and Symptom Management 2003;25(5, Suppl.), S18–S30PubMedCrossRefGoogle Scholar
  46. 46.
    Cassidy J, Bjarnason GA, Hickish T, Topham C, Provencio M, Bodoky G, et al. Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5-FU/LV combination (FOLFOX4) in first line treatment of patients with metastatic colorectal cancer, 2006, [Abstract 229].Google Scholar
  47. 47.
    Cavaletti G, Petruccioli MG, Marmiroli P, Rigolio R, Galbiati S, Zoia C, et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Research 2002;22(6C):4199–4204.PubMedGoogle Scholar
  48. 48.
    Boehmke MM, Dickerson SS. Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nursing 2005;28:382–389.PubMedCrossRefGoogle Scholar
  49. 49.
    Cascinu S, Catalano V, Cordella L, Lubianca R, Giordano P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2002;20:3478–3483PubMedCrossRefGoogle Scholar
  50. 50.
    Cassidy J, Misset JL. Oxaliplatin-related side effects: Characteristics and management. Seminars in Oncology 2002;29(Suppl. 15):11–20.PubMedCrossRefGoogle Scholar
  51. 51.
    Cersosimo RJ. Oxaliplatin-associated neuropathy: A review. Annals of Pharmacotherapy 2005;39:128–135.PubMedCrossRefGoogle Scholar
  52. 52.
    Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O’Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002;59:1872–1875.PubMedGoogle Scholar
  53. 53.
    Cianfrocca M, Glatters SJ, Bennett GJ, McNicol E, Relias V, Carr D, et al. Peripheral neuropathy in a woman with breast cancer. Journal of Pain 2006;7:2–10.PubMedCrossRefGoogle Scholar
  54. 54.
    Criscuolo S, Auletta C, Lippi S, Brogi F, Brogi A. Oxcarbazepine (Trileptal®) monotherapy dramatically improves quality of life in two patients with postherpetic neuralgia refractory to carbamazepine and gabapentin. Journal of Pain and Symptom Management 2004;28:535–536.PubMedCrossRefGoogle Scholar
  55. 55.
    De Santis S, Pace A, Bove L, Cognetti F, Properzi F, Fiore M, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clinical Cancer Research 2000;6:90–95.PubMedGoogle Scholar
  56. 56.
    du Bois A, Schlaich M, Lück HJ, Mollenkopf A, Wechsel U, Rauchholz M, et al. Evaluation of neurotoxicity induced by paclitaxel second- line chemotherapy. Supportive Care in Cancer 1999;7:354–361.PubMedCrossRefGoogle Scholar
  57. 57.
    Durand JP, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anti-Cancer Drugs 2005;16:587–591.PubMedCrossRefGoogle Scholar
  58. 58.
    Fine PG, Miaskowski C, Paice JA. Meeting the challenges in cancer pain management. Journal of Supportive Oncology 2004;2(Suppl. 4):5–22.PubMedGoogle Scholar
  59. 59.
    Frisk P, Stalberg E, Stromberg B, Jakobson A. Painful peripheral neuropathy after treatment with high-dose ifosfamide. Medical and Pediatric Oncology 2001;37:379–382.PubMedCrossRefGoogle Scholar
  60. 60.
    Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Seminars in Oncology 2002;29(Suppl. 15):21–33.PubMedCrossRefGoogle Scholar
  61. 61.
    Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research 2004;10:4055–4061. Gornet JM, Savier E, Lokiec F, Cvitkovic E, Misset JL, Goldwasser F. Exacerbation of oxaliplatin neurosensory toxicity following surgery. Annals of Oncology 2002;13:1315–1318.Google Scholar
  62. 62.
    Grothey A. Oxaliplatin—Safety profile: Neurotoxicity. Seminars in Oncology 2003;30(Suppl. 15):5–13.PubMedCrossRefGoogle Scholar
  63. 63.
    HughesRA. Peripheral neuropathy. BMJ 2002;324:466–469Google Scholar
  64. 64.
    Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy. Muscle and Nerve 2004;29:287–292.CrossRefGoogle Scholar
  65. 65.
    Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels Journal of Neurophysiology 2001;85:2293–2297PubMedGoogle Scholar
  66. 66.
    Lazo G, Kantarjian H, Estey E, Thomas D, O’Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia. Cancer 2003;97:2218–2224.PubMedCrossRefGoogle Scholar
  67. 67.
    Lenz G, Hacker UT, Kern W, Schalhorn A, Hiddemann W Adverse reactions to oxaliplatin: A retrospective study of 25 patients treated in one institution. Anti-Cancer Drugs 2003;14:731–733.PubMedCrossRefGoogle Scholar
  68. 68.
    Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, et al. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel induced neurotoxicity: A phase II study of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003;21:4207–4213.PubMedCrossRefGoogle Scholar
  69. 69.
    Nail LM. Long-term persistence of symptoms. Seminars in Oncology Nursing 2001;17:249–254.PubMedCrossRefGoogle Scholar
  70. 70.
    Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology 2006;33:15–49.PubMedCrossRefGoogle Scholar
  71. 71.
    Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. British Medical Journal of Cancer 2005;5:116–126.Google Scholar
  72. 72.
    Marrs J, Newton S. Updating your peripheral neuropathy “know-how.” Clinical Journal of Oncology Nursing 2003;7:299–303.PubMedCrossRefGoogle Scholar
  73. 73.
    Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Supportive Care in Cancer 2004;12:619–625.PubMedGoogle Scholar
  74. 74.
    Openshaw H, Beamon K, Synold TW, Longmate J, Statkin NE, Doroshow JH, et al. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: Lace of neuroprotective effect of amifostine. Clinical Cancer Research 2004;10:461–467.PubMedCrossRefGoogle Scholar
  75. 75.
    Paice JA. Mechanisms and management of neuropathic pain in cancer. Supportive Oncology 2003;1:107–112.PubMedGoogle Scholar
  76. 76.
    Polomano RC, Bennett GJ. Chemotherapy-evoked painful peripheral neuropathy. Pain Medicine 2001;2:8–14.PubMedCrossRefGoogle Scholar
  77. 77.
    Polomano RC, Farrar JT. Pain and neuropathy in cancer survivors. American Journal of Nursing 2006;106(3, Suppl.): 39–47.PubMedGoogle Scholar
  78. 78.
    Poncelet AN. An algorithm for the evaluation of peripheral neuropathy. American Family Physician 1998;57:755–764.PubMedGoogle Scholar
  79. 79.
    Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology 2000;11:509–513.PubMedCrossRefGoogle Scholar
  80. 80.
    Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology 1998;9:739–744.PubMedCrossRefGoogle Scholar
  81. 81.
    Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. Journal of Neurology 2002;249:9–17.PubMedCrossRefGoogle Scholar
  82. 82.
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine 2003;348:2609–2617.PubMedCrossRefGoogle Scholar
  83. 83.
    Saif MW. Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. Journal of Applied Research 2004;4:576–582.PubMedGoogle Scholar
  84. 84.
    Smith EL, Whedon MK, Bookbinder M. Quality improvement of painful peripheral neuropathy. Seminars in Oncology Nursing 2002;18:36–43.PubMedCrossRefGoogle Scholar
  85. 85.
    Sorich J, Taubes B, Wagner A, Hochster H. Oxaliplatin: Practical guidelines for administration. Clinical Journal of Oncology Nursing 2004;8:251–256.PubMedCrossRefGoogle Scholar
  86. 86.
    Storstein A, Vedeler CA. Neurological symptoms as the first signs of cancer: Paraneoplastic encephalomyelitis and sensory neuronopathy. American Journal of Oncology Review 2005;4:31–34.Google Scholar
  87. 87.
    Susman E. Xaliproden lessens oxaliplatin-mediated neuropathy. Lancet Oncology 2006;7:288.PubMedCrossRefGoogle Scholar
  88. 88.
    Sweeney CW. Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clinical Journal of Oncology Nursing 2002;6:163–166.PubMedCrossRefGoogle Scholar
  89. 89.
    Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: Atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002;94:2434–2440.PubMedCrossRefGoogle Scholar
  90. 90.
    Tournigand C, Cervantes A, Figer A, Lledo G, Flesh M, Buyse M, et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 in a stop-and-go fashion in advanced colorectal cancer—A GERCOR study. Journal of Clinical Oncology 2006;24:394–400.PubMedCrossRefGoogle Scholar
  91. 91.
    Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complication of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 2003;63:1549–1563.PubMedCrossRefGoogle Scholar
  92. 92.
    Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005;64:1076–1077.PubMedGoogle Scholar
  93. 93.
    Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Investigation 2003;21:439–451.PubMedCrossRefGoogle Scholar
  94. 94.
    Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp K.S. Case report: Painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clinical Journal of Oncology Nursing 2005;9:189–193.PubMedCrossRefGoogle Scholar
  95. 95.
    Wilkes GM. Therapeutic options in the management of colon cancer: 2005 update. Clinical Journal of Oncology Nursing 2005;9:31–44.PubMedCrossRefGoogle Scholar
  96. 96.
    Willis WD. The nervous system. In R.M. Berne M.N. Levy (Eds.), Principles of physiology. Mosby, St. Louis, 2000, pp. 68–94.Google Scholar
  97. 97.
    Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. Journal of Clinical Oncology 2002;20:1767–1774.PubMedCrossRefGoogle Scholar
  98. 98.
    Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, et al. A phase II study of oxaliplatin and paclitaxel inpatients with advanced non-small-cell lung cancer. Annals of Oncology 2004;15:915–920PubMedCrossRefGoogle Scholar
  99. 99.
    Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Research Reviews 2006 Aug;51(2):240–64.PubMedCrossRefGoogle Scholar
  100. 100.
    Watkins LR, Hutchinson MR, Milligan ED, Maier SF. Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Research Review 2007;56(1):148–69.CrossRefGoogle Scholar
  101. 101.
    Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain, Behavior, and Immunity 2007;21(2):131–46.PubMedCrossRefGoogle Scholar
  102. 102.
    Wieseler-Frank J, Jekich BM, Mahoney JH, Bland ST, Maier SF, Watkins LR. A novel immune-to-CNS communication pathway: cells of the meninges surrounding the spinal cord CSF space produce proinflammatory cytokines in response to an inflammatory stimulus. Brain, Behavior, and Immunity 2007;21(5):711–8.PubMedCrossRefGoogle Scholar
  103. 103.
    Banks WA, Watkins LR. Mediation of chronic pain: not by neurons alone. Pain 2006 Sep;124(1–2):1–2.PubMedCrossRefGoogle Scholar
  104. 104.
    Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. Trends in Neuroscience 2005;28(12):661–9.Google Scholar
  105. 105.
    Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005;14(4):166–74.PubMedCrossRefGoogle Scholar
  106. 106.
    Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J, O'Connor K, Martin D, Forsayeth JR, Maier SF, Johnson K, Chavez RA, Leinwand LA, Watkins LR. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. European Journal of Neuroscience 2005;21(8):2136–48.PubMedCrossRefGoogle Scholar
  107. 107.
    Wieseler-Frank J, Maier SF, Watkins LR. Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain, Behavior Immunity 2005;19(2):104–11.CrossRefGoogle Scholar
  108. 108.
    Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. Journal of International Medecine 2005;257(2):139–55.CrossRefGoogle Scholar
  109. 109.
    Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nature Reviews Drug Discovery 2003;2(12):973–85.PubMedCrossRefGoogle Scholar
  110. 110.
    Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ,Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Archives of Neurology 2003;60(11):1524–34.PubMedCrossRefGoogle Scholar
  111. 111.
    Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Advances in Experimental Medecine and Biology 2003;521:1–21Google Scholar
  112. 112.
    Maier SF, Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain, Behavior, and Immunity 2003;17 Suppl 1:S125–31.PubMedCrossRefGoogle Scholar
  113. 113.
    Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiological Reviews 2002;82(4):981–1011.PubMedGoogle Scholar
  114. 114.
    Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends in Neuroscience 2001 Aug;24(8):450–5.CrossRefGoogle Scholar
  115. 115.
    White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proceedings of the National Academy of the Science of the USA. 2007 Dec 18;104(51):20151–8. Epub 2007 Dec 14.Google Scholar
  116. 116.
    Watkins, LR. Immune and glial regulation of pain Brain, Behavior, and Immunity 2007;21(5):519–521.Google Scholar
  117. 117.
    Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral Inflammation is Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans. Biological Psychiatry 2008;63:1022–1029.PubMedCrossRefGoogle Scholar
  118. 118.
    Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. Journal of Clinical Oncology 2007 May 10;25(14):1858–69.PubMedCrossRefGoogle Scholar
  119. 119.
    Meghani SH, Keane A. Preference for analgesic treatment for cancer pain among African Americans. Journal of Pain and Symptom Management. 2007 Aug;34(2):136–47.PubMedCrossRefGoogle Scholar
  120. 120.
    Altilio T. Pain and symptom management clinical, policy, and political perspectives. Journal of Psychosocial Oncology 2006;24(1):65–79.PubMedCrossRefGoogle Scholar
  121. 121.
    Randall-David E, Wright J, Porterfield DS, Lesser G. Barriers to cancer pain management: home-health and hospice nurses and patients. Supportive Care in Cancer 2003 Oct;11(10):660–5.PubMedCrossRefGoogle Scholar
  122. 122.
    Anderson KO, Richman SP, Hurley J, Palos G, Valero V, Mendoza TR, Gning I, Cleeland CS. Cancer pain management among underserved minority outpatients: perceived needs and barriers to optimal control. Cancer 2002 ;94(8):2295–304.PubMedCrossRefGoogle Scholar
  123. 123.
    Maxwell T. Cancer pain management in the elderly. Geriatr Nursing 2000 May–Jun;21(3):158–63.CrossRefGoogle Scholar
  124. 124.
    Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999 May 15;353(9165):1695–700PubMedCrossRefGoogle Scholar
  125. 125.
    Cleeland CS. Undertreatment of cancer pain in elderly patients. The Journal of the American Medical Association 1998 Jun 17;279(23):1914–5.CrossRefGoogle Scholar
  126. 126.
    Rich BA. A legacy of silence: bioethics and the culture of pain. Journal of Medical Humanities 1997 Winter;18(4):233–59.PubMedCrossRefGoogle Scholar
  127. 127.
    Grossman SA. Undertreatment of cancer pain: barriers and remedies. Supportive Care in Cancer 1993;1(2):74–8.PubMedCrossRefGoogle Scholar
  128. 128.
    Green C, Todd KH, Lebovits A, Francis M; American Academy of Pain MedicineCouncil on Ethics. Disparities in pain: ethical issues. Pain Medicine 2006;7(6):530–3.PubMedCrossRefGoogle Scholar
  129. 129.
    Green CR, Anderson KO, Baker TA, Campbell LC, Decker S, Fillingim RB,Kalauokalani DA, Lasch KE, Myers C, Tait RC, Todd KH, Vallerand AH. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Medicine 2003;4(3):277–94.PubMedCrossRefGoogle Scholar
  130. 130.
    Bandrés E, Zárate R, Ramirez N, Abajo A, Bitarte N, Garíia-Foncillas J. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy. World Journal of Gastroenterology 2007 Nov 28;13(44):5888–901.PubMedGoogle Scholar
  131. 131.
    Mielke S. Individualized pharmacotherapy with paclitaxel. Current Opinion Oncology 2007 Nov;19(6):586–9.CrossRefGoogle Scholar
  132. 132.
    Rekhadevi PV, Sailaja N, Chandrasekhar M, Mahboob M, Rahman MF, Grover P. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis 2007 Nov;22(6):395–401.PubMedCrossRefGoogle Scholar
  133. 133.
    Wang J, Huang Y. Pharmacogenomics of sex difference in chemotherapeutic toxicity. Current Drug Discovery Technology 2007 Jun;4(1):59–68.CrossRefGoogle Scholar
  134. 134.
    Stoehlmacher J. Prediction of efficacy and side effects of chemotherapy in colorectal cancer. Recent Results in Cancer Research 2007;176:81–8.PubMedCrossRefGoogle Scholar
  135. 135.
    Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? British Journal of Cancer 2007 Jul 16;97(2):145–51.PubMedCrossRefGoogle Scholar
  136. 136.
    Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal Clinical Oncology 2007;25(16):2205–11.CrossRefGoogle Scholar
  137. 137.
    Baba H, Doubell TP, Woolf CJ. Peripheral inflammation facilitates Abeta fiber-mediated synaptic input to the substantia gelatinosa of the adult rat spinal cord. Journal of Neuroscience;19(2):859–67.Google Scholar
  138. 138.
    Dantzer R, Capuron L, Irwin MR, Miller AH, Ollat H, Hugh Perry V, Rousey S, Yirmiya R. Identification and treatment of symptoms associated with inflammation inmedically ill patients. Psychoneuroendocrinology. 2008;33(1):18–29.PubMedCrossRefGoogle Scholar
  139. 139.
    Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW.From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 2008;9(1):46–56.PubMedCrossRefGoogle Scholar
  140. 140.
    Dimsdale JE, Dantzer R. A biological substrate for somatoform disorders: importance of pathophysiology. Psychosomatic Medicine. 2007;69(9):850–4.PubMedCrossRefGoogle Scholar
  141. 141.
    Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience. 2008;9(1):46–56.PubMedCrossRefGoogle Scholar
  142. 142.
    Dantzer R. Cytokine, sickness behavior, and depression. Neurologic Clinics 2006; 24(3):441–60.PubMedCrossRefGoogle Scholar
  143. 143.
    Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity 2007;21(2):153–60.PubMedCrossRefGoogle Scholar
  144. 144.
    Dantzer R. Cytokine, sickness behavior, and depression. Neurologic Clinics 2006;24(3):441–60.PubMedCrossRefGoogle Scholar
  145. 145.
    Dantzer R. Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology 2005;30(10):947–52PubMedCrossRefGoogle Scholar
  146. 146.
    Coussens LM, Werb Z. Inflammation and cancer. Nature 2002 ;420(6917):860–7.PubMedCrossRefGoogle Scholar
  147. 147.
    Jan H. Houtveen and Lorenz J.P. van DoornenMedically unexplained symptoms and between-group differences in 24-h ambulatory recording of stress physiology Biological Psychology, Volume 76, Issue 3, October 2007, Pages 239–249CrossRefGoogle Scholar
  148. 148.
    Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1–2):1–18.PubMedCrossRefGoogle Scholar
  149. 149.
    Matzinger P. Friendly and dangerous signals: is the tissue in control? Nature Immunology 2007 Jan;8(1):11–3.PubMedCrossRefGoogle Scholar
  150. 150.
    Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301–5.PubMedCrossRefGoogle Scholar
  151. 151.
    Melzack R, Wall PD. Pain mechanisms: a new theory. Science.1965; 150:971 –9; Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. Journal of Bone and Joint Surgergy American. 2007;89(6):1343–58Google Scholar
  152. 152.
    Apolone G, et al. Pain in Cancer: An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health and Quality of Life Outcomes 2006;4:7.PubMedCrossRefGoogle Scholar
  153. 153.
    Ballantyne JC. Chronic Pain Following Treatment for Cancer: The Role of Opioids. Oncologist 2003; 8: 567–575.PubMedCrossRefGoogle Scholar
  154. 154.
    Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in pain and variability in analgesic drug response. Journal of Pharmacy and Pharmaceutical Sciences 2007;10(4):554–66.PubMedGoogle Scholar
  155. 155.
    Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. The New England Journal of Medicine 1994 Mar 3;330(9):592–6.PubMedCrossRefGoogle Scholar
  156. 156.
    Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing 2007;11(6):901–13.PubMedCrossRefGoogle Scholar
  157. 157.
    Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. European Journal of Cancer 2002;38:1832–1837.PubMedCrossRefGoogle Scholar
  158. 158.
    Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G, Plasmati R, Pastorelli F, Caraceni A, Pace A, Manicone M, Lissoni A, Colombo N, Bianchi G, Zanna C; Italian NETox Group. The Total Neuropathy Score as an assessment tool for grading the course ofchemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. Journal of Peripheral Nervous System 2007 Sep;12(3):210–5.CrossRefGoogle Scholar
  159. 159.
    Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Franchi D, La Presa MT, Lissoni A, Buda A, Fei F, Cundari S, Zanna C. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxelcombination chemotherapy. Annals of Oncology 2004 Sep;15(9):1439–42.PubMedCrossRefGoogle Scholar
  160. 160.
    Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003 Nov 11;61(9):1297–300.PubMedGoogle Scholar
  161. 161.
    Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. European Journal of Cancer 2002 Sep;38(14):1832–7PubMedCrossRefGoogle Scholar
  162. 162.
    Armstrong T, Almadrones L, Gilbert M. Chemotherapyinduced peripheral neuropathy. Oncology Nursing Forum 2005;32:305–311.PubMedCrossRefGoogle Scholar
  163. 163.
    Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. European Journal of Cancer 2005;41:1746–1750.PubMedCrossRefGoogle Scholar
  164. 164.
    Bove L, Picardo M, Maresca V, Jandolo B, Pace A. A pilot study on the relation between cisplatin neuropathy and vitamin E. Journal of Experimental and Clinical Cancer Research 2001;20:277–280.Google Scholar
  165. 165.
    Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. Journal of Clinical Oncology 1995;13:26–32.PubMedGoogle Scholar
  166. 166.
    Bartolomucci A, Palanza P, Sacerdote P, Panerai AE, Sgoifo A, Openshaw H, Beamon K, Synod TW, Longmate J, Slatkin NE, Doroshaw JH, et al. Neurophysiolgical study of peripheral neuropathy after high-dose paclitaxel: Lack of neuroprotective effect of amifostine. Clinical Cancer Research 2004;10:461–467.CrossRefGoogle Scholar
  167. 167.
    Wolfe GI, Trivedi JR. Painful peripheral neuropathy and its nonsurgical treatment. Muscle and Nerve 2004;30:3–19.PubMedCrossRefGoogle Scholar
  168. 168.
    Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: A long-term study. Diabetes Research and Clinical Practice 1998;39:115–121.PubMedCrossRefGoogle Scholar
  169. 169.
    Almadrones L, Arcot R. Patient guide to peripheral neuropathy. Oncology Nursing Forum 1999;26:1359–1360.PubMedGoogle Scholar
  170. 170.
    Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. Neurology 2005;64:26–31.PubMedGoogle Scholar
  171. 171.
    Armstrong T, Almadrones L, Gilbert M. Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum 2005;32:305–311.PubMedCrossRefGoogle Scholar
  172. 172.
    Arnall DA, Nelson AG, Lopez L, Sanz N, Iversen L, Sanz I, et al. The restorative effects of pulsed infrared light therapy on significant loss of peripheral protective sensation in patients with long-term type 1 and type 2 diabetes mellitus. Acta Diabetologica 2006;43:26–33.PubMedCrossRefGoogle Scholar
  173. 173.
    Ashton-Miller J, Yeh M, Richardson JK, Galloway T. A cane reduces loss of balance in patients with peripheral neuropathy: Results from a challenging unipedal balance test. Archives of Physical Medicine and Rehabilitation 1996;77:446–452.PubMedCrossRefGoogle Scholar
  174. 174.
    Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. Journal of Diabetes and Its Complications 2006;20:216–223.PubMedCrossRefGoogle Scholar
  175. 175.
    Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. European Journal of Cancer 2005;41:1746–1750.PubMedCrossRefGoogle Scholar
  176. 176.
    Bove L, Picardo M, Maresca V, Jandolo B, Pace A. A pilot study on the relation between cisplatin neuropathy and vitamin E. Journal of Experimental and Clinical Cancer Research 2001;20:277–280.Google Scholar
  177. 177.
    Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2002;20:3478–3483.PubMedCrossRefGoogle Scholar
  178. 178.
    Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. Journal of Clinical Oncology 1995;13:26–32.PubMedGoogle Scholar
  179. 179.
    Cata JP, Cordella JV, Burton AW, Hassenbusch SJ, Weng HR, Dougherty PM. Spinal cord stimulation relieves chemotherapy-induced pain: A clinical case report. Journal of Pain and Symptom Management 2004;27:72–78.PubMedCrossRefGoogle Scholar
  180. 180.
    Davis ID, Kiers L, MacGregor L, Quinn M, Arezzo J, Green M, et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clinical Cancer Research 2005;11:1890–1898.PubMedCrossRefGoogle Scholar
  181. 181.
    Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study.] Deutsche Medizinische Wochenschrift 2002;127:78–82.PubMedCrossRefGoogle Scholar
  182. 182.
    Hammack J, Michalak J, Loprinzi C, Sloan J, Novotny P, Soori G, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cisplatinum-induced peripheral neuropathy. Pain 2002;98:195–203.PubMedCrossRefGoogle Scholar
  183. 183.
    Hilpert F, Stahle A, Tome O, Burges A, Rossner D, Spathe K, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy. A double blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Supportive Care in Cancer 2005;13:797–805.PubMedCrossRefGoogle Scholar
  184. 184.
    Jiang H, Shi K, Li X, Zhou W, Cao Y. Clinical study on the wrist-ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis. Journal of Traditional Chinese Medicine 2006;26:8–12.PubMedGoogle Scholar
  185. 185.
    Forst T, Nguyen M, Forst S, Disselhoff B, Pohlmann T, Pfutzner A. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes, Nutrition and Metabolism 2004;17:163–168.PubMedGoogle Scholar
  186. 186.
    Forst T, Pohlmann T, Kunt T, Goitom K, Schulz G, Lobig M, et al. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy. Acta Diabetologica 2002;39:1–6.PubMedCrossRefGoogle Scholar
  187. 187.
    Phillips KD, Skelton WD, Hand GA. Effect of acupuncture administered in a group setting on pain and subjective peripheral neuropathy in persons with human immunodeficiency virus disease. Journal of Alternative and Complementary Medicine 2004;10:449–455.CrossRefGoogle Scholar
  188. 188.
    Prendergast JJ, Miranda G, Sanchez M. Improvement of sensory impairment in patients with peripheral neuropathy. Endocrine Practice 2004;10:24–30.PubMedGoogle Scholar
  189. 189.
    Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia 2005;48:824–828.PubMedCrossRefGoogle Scholar
  190. 190.
    Gamelin L, Boisdron-Celle M, Delva R, Geurin-Meyer V, Ifrah N, Morel A, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research 2004;10:4055–4061.PubMedCrossRefGoogle Scholar
  191. 191.
    Leonard DR, Farooqi MH, Myers S. Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: A double-blind, randomized, placebo-controlled study with monochromatic near-infrared treatment. Diabetes Care 2004;27:168–172.PubMedCrossRefGoogle Scholar
  192. 192.
    Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Kerckhoffs M, et al. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: A randomized clinical trial. Archives of Physical Medicine and Rehabilitation 1995;76:612–620.PubMedCrossRefGoogle Scholar
  193. 193.
    Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crino L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005;91:135–138.PubMedGoogle Scholar
  194. 194.
    Marrs J, Newton S. Updating your peripheral neuropathy “know how.” Clinical Journal of Oncology Nursing 2003;7:299–303.PubMedCrossRefGoogle Scholar
  195. 195.
    Moore D, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, et al. Limited access trial using amifostine for protection against cisplatin and three hour paclitaxel-induced neurotoxicity: A phase II study of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003;21:4207–4213.PubMedCrossRefGoogle Scholar
  196. 196.
    Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. Journal of Clinical Oncology 2003;21:927–931.PubMedCrossRefGoogle Scholar
  197. 197.
    Richardson JK, Sandman D, Vela S. A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Archives of Physical Medicine and Rehabilitation 2001;82:205–209.PubMedCrossRefGoogle Scholar
  198. 198.
    Richardson JK, Thies S, DeMott T, Ashton-Miller JA. Interventions improve gait regularity in patients with peripheral neuropathy while walking on an irregular surface under low light. Journal of the American Geriatrics Society 2004;52:510–515.PubMedCrossRefGoogle Scholar
  199. 199.
    Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial. JAMA 1998;280:1590–1595.PubMedCrossRefGoogle Scholar
  200. 200.
    Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomized trial Annals of Oncology 1997;8:569–573.PubMedCrossRefGoogle Scholar
  201. 201.
    Stubblefield MD, Vahdat LT, Balmaceda AB, Troxel AB, Hesdorffer CS, Gooch CL. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clinical Oncology 2005;17:271–276.PubMedCrossRefGoogle Scholar
  202. 202.
    Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clinical Cancer Research 2001;7:1192–1197.PubMedGoogle Scholar
  203. 203.
    Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Annals of Oncology 1998;9:1331–1337.PubMedCrossRefGoogle Scholar
  204. 204.
    White CM, Pritchard J, Turner-Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database of Systematic Reviews 2004;4. Art. No.: CD003904. DOI: 10.1002/14651858.CD003904.pub2.Google Scholar
  205. 205.
    Wong R, Sagar S. Acupuncture treatment for chemotherapy-induced peripheral neuropathy—A case series. Acupuncture in Medicine 2006;24(2):87–91PubMedCrossRefGoogle Scholar
  206. 206.
    Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. Journal of Clinical Oncology 2003;21:927–931.PubMedCrossRefGoogle Scholar
  207. 207.
    Phillips KD, Skelton WD, Hand GA. Effect of acupuncture administered in a group setting on pain and subjective peripheral neuropathy in persons with human immunodeficiency virus disease. Journal of Alternative and Complementary Medicine 2004;10:449–455.CrossRefGoogle Scholar
  208. 208.
    Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia 2005;48:824–828.PubMedCrossRefGoogle Scholar
  209. 209.
    Richardson JK, Sandman D, Vela S. A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Archives of Physical Medicine and Rehabilitation 2001;82:205–209.PubMedCrossRefGoogle Scholar
  210. 210.
    Richardson JK, Thies S, DeMott T, Ashton-Miller JA. Interventions improve gait regularity in patients with peripheral neuropathy while walking on an irregular surface under low light. Journal of the American Geriatrics Society 2004;52:510–515.PubMedCrossRefGoogle Scholar
  211. 211.
    Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial. JAMA 1998;280:1590–1595.PubMedCrossRefGoogle Scholar
  212. 212.
    Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomized trial. Annals of Oncology 1997;8:569–573.PubMedCrossRefGoogle Scholar
  213. 213.
    Stubblefield MD, Vahdat LT, Balmaceda AB, Troxel AB, Hesdorffer CS, Gooch CL. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clinical Oncology 2005;17:271–276.PubMedCrossRefGoogle Scholar
  214. 214.
    Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clinical Cancer Research 2001;7:1192–1197.PubMedGoogle Scholar
  215. 215.
    Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Annals of Oncology 1998;9:1331–1337.PubMedCrossRefGoogle Scholar
  216. 216.
    Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. Journal of Bone and Joint Surgery America. 2007;89(6):1343–58.CrossRefGoogle Scholar
  217. 217.
    Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain1993;52:259–85PubMedCrossRefGoogle Scholar
  218. 218.
    Flor H, Nikolajsen L, Staehelin Jensen T. Phantom limb pain: a case of maladaptive CNS plasticity? Nature Reviews Neuroscience 2006 Nov;7(11):873–81.PubMedCrossRefGoogle Scholar
  219. 219.
    Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288:1765–1769.PubMedCrossRefGoogle Scholar
  220. 220.
    Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology 2000;93:1123–1133.PubMedCrossRefGoogle Scholar
  221. 221.
    Macrae WM, Davies HTO. Chronic postsurgical pain. In: Crombie IK, Croft PR, Linton SJ, Leresche L, Von Korff, M, editors. Epidemiology of pain: a report on the Task Force on Epidemiology. Seattle: IASP Press; 1999. pp. 125–142.Google Scholar
  222. 222.
    Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. Genetc basis for individual variations in pain perception and the development of a chronic pain condition. Human Molecular Genetics 2005;14:135–43.CrossRefGoogle Scholar
  223. 223.
    Eisenberg E. Post-surgical neuralgia. Pain 2004;111:3–7; Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965; 150:971 –Google Scholar
  224. 224.
    Shavit Y, Fridel K, Beilin B. Postoperative pain management and proinflammatory cytokines: animal and human studies. Journal of Neuroimmune Pharmacology 2006 Dec;1(4):443–51.PubMedCrossRefGoogle Scholar
  225. 225.
    Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nature Reviews Cancer 2008 Oct 10. [Epub ahead of print].Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.National Cancer Institute, SRLB/DEA, National Institutes of HealthRockvilleUSA

Personalised recommendations